German acromegaly patients interim results from the International Observational Acromegaly Study on impact of sandostatin LAR OASIS

被引：0
|
作者：
Petersenn, S.
Etzrodt, H.
Sievers, C.
Droste, M.
Wallaschofski, H.
Decroix, L.
Stalla, G. K.
机构：
[1] Univ Klinikum Essen, Essen, Germany
[2] Max Planck Inst Psychiat, Dept Neuroendocrinol, D-80804 Munich, Germany
[3] Univ Klinikum Greifswald, Greifswald, Germany
[4] Novartis Pharma GmbH, Nurnberg, Germany
来源：
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES | 2007年 / 115卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P7
引用
收藏
页码：550 / 550
页数：1
相关论文
共 50 条
  • [1] Clinical experience with Sandostatin LAR® in patients with acromegaly
    Heijckmann, CA
    Menheere, PPCA
    Sels, JPJE
    Beuls, EAM
    Wolffenbuttel, BHR
    NETHERLANDS JOURNAL OF MEDICINE, 2001, 59 (06): : 286 - 291
  • [2] Effect of Sandostatin® LAR® on serum leptin levels in patients with acromegaly
    Tan, KCB
    Tso, AWK
    Lam, KSL
    CLINICAL ENDOCRINOLOGY, 2001, 54 (01) : 31 - 35
  • [3] The Incidence of Cancer Among Acromegaly Patients: Results From the German Acromegaly Registry
    Petroff, David
    Toenjes, Anke
    Grussendorf, Martin
    Droste, Michael
    Dimopoulou, Christina
    Stalla, Guenter
    Jaursch-Hancke, Cornelia
    Mai, Manuel
    Schopohl, Jochen
    Schoefl, Christof
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (10): : 3894 - 3902
  • [4] Incidence of myocardial infarction and stroke in acromegaly patients: results from the German Acromegaly Registry
    Christof Schöfl
    David Petroff
    Anke Tönjes
    Martin Grussendorf
    Michael Droste
    Günter Stalla
    Cornelia Jaursch-Hancke
    Sylvère Störmann
    Jochen Schopohl
    Pituitary, 2017, 20 : 635 - 642
  • [5] Incidence of myocardial infarction and stroke in acromegaly patients: results from the German Acromegaly Registry
    Schoefl, Christof
    Petroff, David
    Toenjes, Anke
    Grussendorf, Martin
    Droste, Michael
    Stalla, Guenter
    Jaursch-Hancke, Cornelia
    Stoermann, Sylvere
    Schopohl, Jochen
    PITUITARY, 2017, 20 (06) : 635 - 642
  • [6] Therapeutic effect of presurgical treatment with long-acting octreotide (Sandostatin® LAR®) in patients with acromegaly
    Bolanowski, Marek
    Zgliczynski, Wojciech
    Sowinski, Jerzy
    Baldys-Waligorska, Agata
    Bednarek-Tupikowska, Grazyna
    Witek, Przemyslaw
    Zielinski, Grzegorz
    Liebert, Wlodzimierz
    Sieminska, Lucyna
    Andrysiak-Mamos, Elzbieta
    Marek, Bogdan
    Kajdaniuk, Dariusz
    Maticka, Joanna
    Rosiek, Violetta
    Jawiarczyk-Przybylowskal, Aleksandra
    ENDOKRYNOLOGIA POLSKA, 2020, 71 (04) : 285 - 291
  • [7] Effects of treatment with Sandostatin® LAR® on small dense LDL and remnant-like lipoproteins in patients with acromegaly
    Tan, KCB
    Pang, RWC
    Tiu, SC
    Lam, KSL
    CLINICAL ENDOCRINOLOGY, 2003, 59 (05) : 558 - 564
  • [8] Primary surgical therapy of acromegaly - results and prognostic parameters from the German acromegaly register
    Petersenn, S.
    Quabbe, H. J.
    Reincke, M.
    Franz, H.
    Buchfelder, M.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2007, 115 : S77 - S78
  • [9] Results of a European Multicentre Study with Sandostatin® LAR® in Acromegalic Patients
    Lancranjan I.
    Atkinson A.B.
    Pituitary, 1999, 1 (2) : 105 - 114
  • [10] Fractionated radiotherapy and radiosurgery in acromegaly: analysis of 352 patients from the German Acromegaly Registry
    Knappe, U. J.
    Petroff, D.
    Ouinkler, M.
    Schmid, S. M.
    Schoefl, C.
    Schopohl, J.
    Stieg, M. R.
    Toenjes, A.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2020, 182 (03) : 275 - 284
12345